CRISPR point-of-care test detects TB directly from sputum

Tuberculosis remains a major global health challenge because it can be slow to diagnose and needs laboratory infrastructure that is not always available near patients. In response, researchers led by Cameron Myhrvold developed a streamlined point-of-care CRISPR test designed to work directly from sputum samples. The team focused on simplifying the whole process so that it moves from sample extraction to assay readout in a rapid and robust format. According to the abstract, the new assay is designed to combine amplification and detection in a single workflow, and it is the first test reported to do so while remaining compatible with both lateral flow for simple visual readout and lyophilization for dried, transportable reagents. The study positions this CRISPR-based approach as a potential way to bring accurate TB testing closer to patients, reducing the delay between taking a sputum sample and getting a clear result. By emphasizing speed, simplicity, and compatibility with low-tech readout and storage options, the researchers aim to address barriers that make standard TB testing difficult in many settings.

The abstract summarizes key methods and early results for the assay. Clinical tests used 13 blinded sputum samples and compared results to the microbiological gold standard, TB culture. The assay achieved 100% (6/6) sensitivity and 100% (7/7) specificity versus culture in this small blinded set. The authors report that the assay showed no cross reactivity against a wide range of bacterial/fungal isolates, and the abstract also lists BCG in the context of testing. In addition to matching TB culture in these samples, the assay demonstrated comparable sensitivity to the nucleic acid state-of-the-art, GeneXpert MTB/RIF Ultra. Technically, the platform combines the steps of amplifying target sequences and detecting them in a streamlined format. It is reported to be compatible with lateral flow readouts, which enable simple visual interpretation, and with lyophilization, which supports dried reagent formats for easier transport and storage. Those combined features are emphasized as central technical achievements in the abstract.

If the results described in the abstract hold up in larger studies, this approach could change how and where TB is diagnosed. Matching the sensitivity of TB culture and GeneXpert MTB/RIF Ultra while simplifying the workflow suggests the test could be used closer to the point of care, reducing the time patients wait for definitive results. Compatibility with lateral flow readouts means the test could be read without complex instruments, and lyophilization compatibility suggests reagents could be stored and transported in dried form, easing supply challenges in remote settings. By combining amplification and detection in a single streamlined assay, the technology aims to reduce procedural steps and potential failure points, which could make testing more robust under field conditions. The abstract frames this CRISPR-based test as a rapid, robust option that preserves high sensitivity and specificity while offering practical features valued in low-resource and decentralized health systems.